TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1976487

Group type: EXPERIMENTAL
Intervention: Formoterol 12 micrograms via MDI
Number of subjects: 16

Group type: COMPARATOR
Intervention: Albuterol 200 micrograms via MDI
Number of subjects: 16
Study: 7002949

Group type: EXPERIMENTAL
Intervention: Oral 0.1 N HCl
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oral 30 g glucose
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oral glucose-acid combination
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intraduodenal 20 g glucose
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intraduodenal 75 cc 0.1 N HCl
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intraduodenal glucose-acid combination
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oral glucose-acid load
Number of subjects: 16
Study: 31796827

Group type: EXPERIMENTAL
Intervention: Anodal tDCS of 1-3 mA current intensity for 15-30 minutes
Number of subjects: 16
Study: 27680219

Group type: EXPERIMENTAL
Intervention: Standard/low dose regimen starting at 70% of the minimal erythema dose (MED) with 20% dose increments
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Medium dose regimen starting at 200% MED with 25% increments
Number of subjects: 15
Study: 25874255

Group type: EXPERIMENTAL
Intervention: Herbal mouthwash containing Baccharis dracunculifolia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other mouthwashes
Number of subjects: 0
Study: 23806017

Group type: EXPERIMENTAL
Intervention: Accountable Justifications
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Suggested Alternatives
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Peer Comparison
Number of subjects: 269
Study: 22954754

Group type: EXPERIMENTAL
Intervention: RIS2mg+PIM20mg
Number of subjects: 423

Group type: COMPARATOR
Intervention: RIS2mg+placebo
Number of subjects: 423

Group type: COMPARATOR
Intervention: RIS6mg+placebo
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: HAL2mg+PIM20mg
Number of subjects: 423

Group type: COMPARATOR
Intervention: HAL2mg+placebo
Number of subjects: 423
Study: 19955881

Group type: EXPERIMENTAL
Intervention: Complete Tailored Intervention (CTI)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Tailored Message Intervention (TMI)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Standard Intervention (SI)
Number of subjects: 185
Study: 17571000

Group type: EXPERIMENTAL
Intervention: Frequency-Doubling Technology (FDT)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Short-Wavelength Automated Perimetry (SWAP)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Standard Automated Perimetry (SAP)
Number of subjects: 278
Study: 15823771

Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg sachet for suspension
Number of subjects: 72

Group type: COMPARATOR
Intervention: Lansoprazole 15 mg capsule
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg sachet for suspension
Number of subjects: 72

Group type: COMPARATOR
Intervention: Lansoprazole 30 mg capsule
Number of subjects: 72
Study: 11682319

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9466101

Group type: EXPERIMENTAL
Intervention: 20 mL 0.5% plain bupivacaine
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 20 mL 0.9% saline with 5 mg diamorphine
Number of subjects: 96

Group type: COMPARATOR
Intervention: 20 mL 0.9% saline (control)
Number of subjects: 96
Study: 8180744

Group type: EXPERIMENTAL
Intervention: Picotamide (1200 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Aspirin (325 mg/day)
Number of subjects: 40
Study: 3286360

Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg twice daily
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 31747236

Group type: EXPERIMENTAL
Intervention: FF/VI 100 mcg/25 mcg
Number of subjects: 16485

Group type: EXPERIMENTAL
Intervention: FF 100 mcg
Number of subjects: 16485

Group type: EXPERIMENTAL
Intervention: VI 25 mcg
Number of subjects: 16485

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16485
Study: 27940009

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 26445112

Group type: EXPERIMENTAL
Intervention: GLP-1 (1 pmol × kg(‐1) × min(‐1))
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Glucagon (0.86 pmol × kg(‐1) × min(‐1))
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Oxyntomodulin (3 pmol × kg(‐1) × min(‐1))
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Glucagon + GLP-1 (same doses)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: All peptide infusions
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Oxyntomodulin, GLP-1, and GLP-1 + glucagon
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Glucagon
Number of subjects: 15
Study: 24019546

Group type: EXPERIMENTAL
Intervention: External beam radiation therapy (EBRT) following vaginal radium brachytherapy (n = 288)
Number of subjects: 568

Group type: COMPARATOR
Intervention: Brachytherapy alone (n = 280)
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: External beam radiation therapy (EBRT)
Number of subjects: 568
Study: 22010012

Group type: EXPERIMENTAL
Intervention: S-1 (80 to 120 mg per day for 4 weeks, followed by 2 weeks of rest, repeated for 1 year)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 0
Study: 19564224

Group type: EXPERIMENTAL
Intervention: Three-month structured outpatient intervention using brief psychodynamic psychotherapy
Number of subjects: 87

Group type: COMPARATOR
Intervention: Standard treatment recommended by the Chilean Ministry of Health
Number of subjects: 87
Study: 16458130

Group type: EXPERIMENTAL
Intervention: upstream tirofiban
Number of subjects: 93

Group type: COMPARATOR
Intervention: downstream high-dose bolus tirofiban
Number of subjects: 93

Group type: COMPARATOR
Intervention: abciximab
Number of subjects: 93
Study: 15303805

Group type: EXPERIMENTAL
Intervention: Intra‐articular corticosteroid injections (ICIs)
Number of subjects: 18
Study: 10799192

Group type: EXPERIMENTAL
Intervention: Transvaginal antimicrobial mesh (MycroMesh)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Vaginal wall sling
Number of subjects: 40
Study: 8867875

Group type: EXPERIMENTAL
Intervention: Clonidine (1.5 microgram/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study: 1617766

Group type: EXPERIMENTAL
Intervention: Anistreplase
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study: 6380197

Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30661220

Group type: EXPERIMENTAL
Intervention: Polyphenol-enriched tomato juice (200g with 1g ethanolic extract)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard tomato juice (200g)
Number of subjects: 26
Study: 28385329

Group type: EXPERIMENTAL
Intervention: Benzathine penicillin (BP) - 600,000 IU for children ≤27kg and 1,200,000 IU for children ≥27kg, administered every two weeks for six months.
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Azithromycin (AZT) - 250mg for children ≤25kg and 500mg for children ≥25kg, administered once weekly for six months.
Number of subjects: 350
Study: 26367377

Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 12

Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 12
Study: 23233715

Group type: EXPERIMENTAL
Intervention: modified FOLFOX6 plus bevacizumab (5 mg/kg) once every 2 weeks for 12 months
Number of subjects: 2673

Group type: COMPARATOR
Intervention: modified FOLFOX6 (control group) once every 2 weeks for 6 months
Number of subjects: 2673
Study: 21450639

Group type: EXPERIMENTAL
Intervention: Six-minute walk test (6MWT)
Number of subjects: 88
Study: 19587109

Group type: EXPERIMENTAL
Intervention: Nurse intervention
Number of subjects: 766
Study: 17372327

Group type: EXPERIMENTAL
Intervention: Minimal waist circumference
Number of subjects: 266

Group type: COMPARATOR
Intervention: Umbilical waist circumference
Number of subjects: 266
Study: 15193891

Group type: EXPERIMENTAL
Intervention: Hispanic women with lower acculturation levels
Number of subjects: 767

Group type: COMPARATOR
Intervention: Highly acculturated Hispanic women and non-Hispanic white women
Number of subjects: 767

Group type: COMPARATOR
Intervention: Non-Hispanic white women
Number of subjects: 767
Study: 11836798

Group type: EXPERIMENTAL
Intervention: Salbutamol via Clickhaler (100 microg)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Salbutamol via pMDI plus VHC (100 microg)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Clickhaler
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 61
Study: 10429840

Group type: EXPERIMENTAL
Intervention: Zanamivir 10 mg/day by oral inhalation for 28 days
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 7724714

Group type: EXPERIMENTAL
Intervention: Treatment for major depression in primary care setting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Referral to mental health facility
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other conditions
Number of subjects: 0
Study: 1823578

Group type: EXPERIMENTAL
Intervention: Antioxidant compound (2 tablets daily for 3 weeks)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 7033994

Group type: EXPERIMENTAL
Intervention: Once daily dosage of carbamazepine (mean dose 13.9 mg/dg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Twice daily dosage of carbamazepine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Divided daily doses of carbamazepine (2 to 3 times daily)
Number of subjects: 14
Study: 6145618

Group type: EXPERIMENTAL
Intervention: Pafenolol (beta-blocker more beta 1-selective than metoprolol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prenalterol (selective beta 1-stimulating agent)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metoprolol (beta-blocker)
Number of subjects: 0
Study: 30463830

Group type: EXPERIMENTAL
Intervention: Articaine
Number of subjects: 160

Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 160
Study: 27342377

Group type: EXPERIMENTAL
Intervention: Defined epilepsy nurse role
Number of subjects: 320

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 320
Study: 25525601

Group type: EXPERIMENTAL
Intervention: Breast stimulation
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no breast stimulation)
Number of subjects: 200
Study: 23312051

Group type: EXPERIMENTAL
Intervention: n-3 PUFAs (3 g/day, 1 g three times a day during meals for 6 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20412373

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg
Number of subjects: 984

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 984
Study: 18709812

Group type: COMPARATOR
Intervention: Lubricant gel
Number of subjects: 117

Group type: COMPARATOR
Intervention: Intrarectal lidocaine gel
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Anesthetic blockage with 1% lidocaine
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Pretest anxiety
Number of subjects: 117
Study: 21966755

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE) 0.625 mg/day (group 1)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE) 0.625 mg/day plus chlormadinone 1 mg/day (group 2)
Number of subjects: 18
Study: 12962026

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) administered every month or two months for more than half a year
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9869584

Group type: EXPERIMENTAL
Intervention: 3-day regimen of oral azithromycin (500 mg/day for days 1 to 3)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 5-day regimen of oral azithromycin (500 mg on day 1 and 250 mg/day for days 2 to 5)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both regimens of oral azithromycin
Number of subjects: 12
Study: 8699584

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (n = 20)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (n = 19)
Number of subjects: 39
Study: 1743787

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg
Number of subjects: 18
Study: 6849849

Group type: EXPERIMENTAL
Intervention: Lamicel (synthetic hydrophilic polymer)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 48
Study: 30865288

Group type: EXPERIMENTAL
Intervention: Smartphone-based daily evaluation of mixed symptoms and irritability
Number of subjects: 84
Study: 30383906

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 100 mg/m2 on days 8 and 15 plus CC-486 200 mg daily on days 1 to 14
Number of subjects: 161

Group type: COMPARATOR
Intervention: single-agent nab-paclitaxel 100 mg/m2 on days 1 and 8
Number of subjects: 161
Study: 27271664

Group type: EXPERIMENTAL
Intervention: 400 g of olive fruit polyphenol-enriched yogurt with 50 mg of encapsulated olive polyphenols
Number of subjects: 16

Group type: COMPARATOR
Intervention: 400 g of plain yogurt
Number of subjects: 16
Study: 23485658

Group type: EXPERIMENTAL
Intervention: Preoperative education and administration of intramuscular diclofenac Na 75 mg regardless of pain reporting in the first two postoperative hours
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group received no preoperative education and analgesics only upon pain reporting
Number of subjects: 70
Study: 21824010

Group type: EXPERIMENTAL
Intervention: ASCT treatment (MPD plus RCT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (MPD plus SPC)
Number of subjects: 40
Study: 19236688

Group type: EXPERIMENTAL
Intervention: Automatic Tube Compensation (ATC)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 180
Study: 17990199

Group type: EXPERIMENTAL
Intervention: Hospital-based Rehabilitation
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Integrated Treatment
Number of subjects: 94

Group type: COMPARATOR
Intervention: Standard Treatment
Number of subjects: 94
Study: 16400902

Group type: EXPERIMENTAL
Intervention: 0.4% olopatadine nasal spray
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: 0.6% olopatadine nasal spray
Number of subjects: 565

Group type: COMPARATOR
Intervention: Olopatadine nasal spray (0.4% and 0.6%)
Number of subjects: 565
Study: 12146535

Group type: EXPERIMENTAL
Intervention: Delayed implantation (Group 2)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Immediate implantation (Group 1)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Late implantation (Group 3)
Number of subjects: 66
Study: 9532321

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide nasal spray (42 mcg/nostril t.i.d.)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide nasal spray (84 mcg/nostril t.i.d.)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Placebo (saline vehicle)
Number of subjects: 219
Study: 7977225

Group type: EXPERIMENTAL
Intervention: Mesalazine
Number of subjects: 1022

Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Number of subjects: 1022

Group type: EXPERIMENTAL
Intervention: Sulfasalazine or Mesalazine
Number of subjects: 1022
Study: 3288292

Group type: EXPERIMENTAL
Intervention: 1 g pulsed methylprednisolone
Number of subjects: 71

Group type: COMPARATOR
Intervention: 500 mg pulsed methylprednisolone
Number of subjects: 71

Group type: COMPARATOR
Intervention: 40 mg pulsed methylprednisolone
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 71
Study: 12305415

Group type: EXPERIMENTAL
Intervention: 10 mg dienestrol following each intercourse
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2.5 mg dienestrol and 0.2 mg ethynodiol‐diacetate
Number of subjects: 30
Study: 30684048

Group type: EXPERIMENTAL
Intervention: Prophylactic antiemetics (primarily prokinetics such as metoclopramide and domperidone)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Prokinetics (metoclopramide and domperidone)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: 5-HT3 antagonists
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Neuroleptic antipsychotics
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Prokinetics (at occurrence of OINV)
Number of subjects: 112
Study: 27485808

Group type: EXPERIMENTAL
Intervention: Floorball training (FG)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Petanque group (PG)
Number of subjects: 39
Study: 25723472

Group type: EXPERIMENTAL
Intervention: Raltegravir (RAL)
Number of subjects: 541

Group type: COMPARATOR
Intervention: Control (lopinavir/ritonavir with nucleoside/nucleotide reverse transcriptase inhibitors)
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: RAL
Number of subjects: 541
Study: 24565238

Group type: EXPERIMENTAL
Intervention: Bupivacaine S75-R25 with epinephrine 1:200,000 (bupi)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Ropivacaine (ropi)
Number of subjects: 44
Study: 20971744

Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (pPCI)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Fibrinolysis
Number of subjects: 266
Study: 19212877

Group type: EXPERIMENTAL
Intervention: NGX267
Number of subjects: 0
Study: 17207326

Group type: EXPERIMENTAL
Intervention: Recombinant LH (rLH) supplementation
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control (no rLH supplementation)
Number of subjects: 5
Study: 14759456

Group type: EXPERIMENTAL
Intervention: Continuous retrograde cold blood cardioplegia
Number of subjects: 70

Group type: COMPARATOR
Intervention: Intermittent retrograde cold blood cardioplegia
Number of subjects: 70
Study: 11759784

Group type: EXPERIMENTAL
Intervention: Enhanced physical activity and nutrition interventions (EI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Minimum interventions (MI)
Number of subjects: 0
Study: 9010421

Group type: EXPERIMENTAL
Intervention: Gamma knife radiosurgery
Number of subjects: 8
Study: 8328732

Group type: EXPERIMENTAL
Intervention: Misoprostol, 200 micrograms, four times a day for 12 weeks
Number of subjects: 638

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 638
Study: 3530858

Group type: EXPERIMENTAL
Intervention: 100 mg Acarbose with 100 g sucrose load
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo with 100 g sucrose load
Number of subjects: 9
Study: 30328494

Group type: EXPERIMENTAL
Intervention: Oxytocin infusion (10 IU in 500 ml saline at 120 ml/h)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 0
Study: 29894461

Group type: EXPERIMENTAL
Intervention: V‐shaped minimal facelift incision (FLI)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Modified Blair incision (MBI)
Number of subjects: 46
Study: 27391484

Group type: COMPARATOR
Intervention: High GI (GI ≥65) with high %carb (58 % kcal) (reference diet)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Low GI (≤45) with low %carb (40 % kcal)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Low GI with high %carb
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Reducing GI
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Cystatin C and β2M
Number of subjects: 163
Study: 24449626

Group type: EXPERIMENTAL
Intervention: Transradial approach (TRA)
Number of subjects: 836

Group type: COMPARATOR
Intervention: Transfemoral approach (TFA)
Number of subjects: 836
Study: 22928433

Group type: EXPERIMENTAL
Intervention: Cryotherapy/compression device (group 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standardized ice pack (group 2)
Number of subjects: 0
Study: 19652108

Group type: EXPERIMENTAL
Intervention: Kefir drink
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo (heat-killed matching placebo)
Number of subjects: 125
Study: 17473774

Group type: EXPERIMENTAL
Intervention: High-protein diet (3.6 g.kg(‐1); HP)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Low-protein diet (0.8 g.kg(‐1); LP)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Moderate-protein diet (1.8 g.kg(‐1); MP)
Number of subjects: 5
Study: 15051932

Group type: EXPERIMENTAL
Intervention: AST-120 (6.0 g/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Non-AST-120 (control)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 50
Study: 11576048

Group type: EXPERIMENTAL
Intervention: Remifentanil (0.5 microg x kg(‐1) x min(‐1)) combined with propofol (target plasma concentration of 1.5 microg x ml(‐1))
Number of subjects: 16

Group type: COMPARATOR
Intervention: Isoflurane (1.8 %, 1.5 MAC)
Number of subjects: 16
Study: 8135569

Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation (Elevit Pronatal)
Number of subjects: 3713

Group type: COMPARATOR
Intervention: Trace elements
Number of subjects: 3713
Study: 2597519

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (EPO)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 4458770

Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metoclopramide 20 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diazepam 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study: 31560223

Group type: EXPERIMENTAL
Intervention: Hearing Aids (HA)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Hearing Aids (HA) + Frequency Modulated (FM) system
Number of subjects: 31

Group type: COMPARATOR
Intervention: Normal Hearing (NH)
Number of subjects: 31
Study: 30862584

Group type: EXPERIMENTAL
Intervention: New decision tree model for prognosis prediction
Number of subjects: 507

Group type: COMPARATOR
Intervention: Tokuhashi score
Number of subjects: 507

Group type: COMPARATOR
Intervention: Tomita score
Number of subjects: 507
Study: 28081288

Group type: EXPERIMENTAL
Intervention: Short implants (6 mm; GS/group short)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Long implants (11-15 mm; GG/group graft)
Number of subjects: 101
Study: 25884448

Group type: EXPERIMENTAL
Intervention: 6 cycles of neo‐adjuvant oxaliplatin‐based chemotherapy followed by surgery (arm B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery alone (standard treatment, arm A)
Number of subjects: 0
Study: 23228215

Group type: EXPERIMENTAL
Intervention: HES (130/0.4)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Ringer's lactate (RL)
Number of subjects: 24